0001104659-16-131384.txt : 20160706
0001104659-16-131384.hdr.sgml : 20160706
20160706212246
ACCESSION NUMBER: 0001104659-16-131384
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160706
FILED AS OF DATE: 20160706
DATE AS OF CHANGE: 20160706
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001556263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453772460
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 ARSENAL STREET
STREET 2: SUITE 130
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-744-1340
MAIL ADDRESS:
STREET 1: 480 ARSENAL STREET
STREET 2: SUITE 130
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: LS22, Inc.
DATE OF NAME CHANGE: 20120815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NELSEN ROBERT
CENTRAL INDEX KEY: 0001219042
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37813
FILM NUMBER: 161755407
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
4
1
a4.xml
4
X0306
4
2016-07-06
0
0001556263
Syros Pharmaceuticals, Inc.
SYRS
0001219042
NELSEN ROBERT
C/O ARCH VENTURE PARTNERS
8755 WEST HIGGINS ROAD, SUITE 1025
CHICAGO
IL
60631
1
0
1
0
Common Stock
2016-07-06
4
C
0
266666
A
479999
I
See footnote
Common Stock
2016-07-06
4
C
0
1333333
A
1813332
I
See footnote
Common Stock
2016-07-06
4
C
0
2000000
A
3813332
I
See footnote
Common Stock
2016-07-06
4
C
0
423805
A
4237137
I
See footnote
Common Stock
2016-07-06
4
P
0
400000
12.50
A
4637137
I
See footnote
Series A-1 Preferred Stock
2016-07-06
4
C
0
1000000
0
D
Common Stock
266666
0
I
See footnote
Series A-2 Preferred Stock
2016-07-06
4
C
0
5000000
0
D
Common Stock
1333333
0
I
See footnote
Series A-3 Preferred Stock
2016-07-06
4
C
0
7500000
0
D
Common Stock
2000000
0
I
See footnote
Series B Preferred Stock
2016-07-06
4
C
0
1589269
0
D
Common Stock
423805
0
I
See footnote
The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.
/s/Mark McDonnell, as attorney-in-fact for Robert Nelsen
2016-07-06